Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Dipti Patel-Donnelly"'
Autor:
Wael A. Harb, Barbara Klencke, Prapti A. Patel, Kelly McCaul, Ayad Al-Katib, Nehal Lakhani, Jason R. Westin, Dipti Patel-Donnelly, Michael B. Maris, Carolina Escobar, Caron A. Jacobson
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:52-59
Background PNT2258 is a liposomal formulation that encapsulates multiple copies of PNT100, a native, chemically unmodified, 24-base DNA oligonucleotide designed to target the regulatory region upstream of the B-cell lymphoma 2 (BCL2) gene. Methods Th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb37411b9b374322d3b523ccfeb125e4
https://doi.org/10.1016/j.clml.2021.07.020
https://doi.org/10.1016/j.clml.2021.07.020
Autor:
Christopher A. Yasenchak, Rodolfo Bordoni, Dipti Patel-Donnelly, Timothy Larson, Jerome Goldschmidt, Ralph V. Boccia, Vivian J.M. Cline, Adrija Mamidipalli, Jingmin Liu, Joseph T. Beck
Publikováno v:
Blood. 140:3685-3686
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e32290e674c1ae0de66b82799d0b2dbd
https://doi.org/10.1182/blood-2022-156567
https://doi.org/10.1182/blood-2022-156567
Autor:
Sarit Assouline, Brian T. Hill, Wei Ye, Farrukh T. Awan, Arati V. Rao, Jeff P. Sharman, Michael J. Thirman, Dipti Patel-Donnelly
Publikováno v:
Leukemialymphoma. 60(8)
Entospletinib (GS-9973), an oral, selective inhibitor of spleen tyrosine kinase (SYK), was evaluated as monotherapy in this multicenter, phase 2 study (NCT01799889) of 49 patients with relapsed or refractory chronic lymphocytic leukemia (CLL), includ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e51e6088995b27800144a03580e5e5b7
https://pubmed.ncbi.nlm.nih.gov/30633573
https://pubmed.ncbi.nlm.nih.gov/30633573
Autor:
Matthew Mei, Christopher A. Yasenchak, Rodolfo Bordoni, Dipti Patel-Donnelly, Timothy S. Larson, Robert B. Sims, Victor Yazbeck
Publikováno v:
Journal of Clinical Oncology. 38:TPS8069-TPS8069
TPS8069 Background: Older patients and those with significant comorbidities have not attained outcomes seen in younger patients with classical Hodgkin lymphoma (cHL) and CD30-expressing peripheral T-cell lymphoma (PTCL). Five-year progression-free su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7d027af47ff4ff37d189a3f968841883
https://doi.org/10.1200/jco.2020.38.15_suppl.tps8069
https://doi.org/10.1200/jco.2020.38.15_suppl.tps8069
Autor:
Dipti Patel-Donnelly, Loretta J. Nastoupil, Nehal Lakhani, Taimur Sher, Candace A. Fuchs, Marshall T. Schreeder, Stephen M. Ansell, Wael A. Harb, Lydia B King, Catherine Diefenbach, Darrell Nix, Jonathan B. Cohen, Patricia Sandra Graham, Sarah C. Rutherford, David M. Aboulafia, Jeremy S. Abramson, Henri Lichenstein, Langdon L. Miller, Peter L. Young, Sean Landrette
Publikováno v:
Journal of Clinical Oncology. 38:8017-8017
8017 Background: LAM-002 is a selective inhibitor of PIKfyve that disrupts lysosomal homeostasis, inducing cytotoxicity in B-cell lymphoma models as monotherapy or with anti-CD20 or anti-PDL1 antibodies (Gayle et al., Blood 2017;129(13):1768). Method
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2fd3663ef8e6af03e4920e443cba6a73
https://doi.org/10.1200/jco.2020.38.15_suppl.8017
https://doi.org/10.1200/jco.2020.38.15_suppl.8017
Autor:
Robert T. Chen, Jay Yang, Andrei R. Shustov, Dipti Patel-Donnelly, Jeff P. Sharman, Sarit Assouline, John M. Burke, Wei Ye, James Essell, Wen Shi
Publikováno v:
Clinical lymphoma, myeloma & leukemia
In an open-label, phase II study, we evaluated entospletinib monotherapy for patients with relapsed or refractory diffuse large B-cell lymphoma. Entospletinib had limited activity in these patients. Seventy-four percent of the patients experienced a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30aee4e9a551c1876546d939a38a1505
https://pubmed.ncbi.nlm.nih.gov/29934062
https://pubmed.ncbi.nlm.nih.gov/29934062
Autor:
Yinghui Wang, Andres Forero-Torres, Robert T. Chen, Christopher A. Yasenchak, Vivian Jean M. Cline, Patrick J. Flynn, Dipti Patel Donnelly, Abraham P. Fong, Rodolfo Bordoni, Jonathan W. Friedberg, Gregg Olsen
Publikováno v:
Blood. 130(26)
Patients aged ≥60 years with treatment-naive Hodgkin lymphoma (HL) have few treatment options and inferior survival due to treatment-related toxicities and comorbidities. This phase 2, nonrandomized, open-label study evaluated brentuximab vedotin (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fa2cb11a6a5281970887ae0ec84a845
https://pubmed.ncbi.nlm.nih.gov/29284610
https://pubmed.ncbi.nlm.nih.gov/29284610
Autor:
Matthew Mei, Victor Yazbeck, Linda Ho, Christopher A. Yasenchak, Dipti Patel-Donnelly, Timothy S. Larson, Rodolfo Bordoni, Trevor Newhook
Publikováno v:
Blood. 134:2852-2852
Background Despite the advances in therapy of classical Hodgkin lymphoma (cHL) and CD30-expressing peripheral T-cell lymphoma (PTCL) over the years, the outcomes seen in younger patients with the disease have not been attained in patients ≥60 years
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::88345ee4e0adb5d72c3a9cfe18df4a43
https://doi.org/10.1182/blood-2019-122968
https://doi.org/10.1182/blood-2019-122968
Autor:
Timothy S. Larson, Jonathan W. Friedberg, Christopher A. Yasenchak, Linda Ho, Victor Yazbeck, Rodolfo Bordoni, Matthew Mei, Thomas Anderson, Dipti Patel-Donnelly, Trevor Newhook
Publikováno v:
Blood. 134:237-237
Background. In patients with Hodgkin lymphoma (HL) aged ≥60 years, comorbidities and treatment-related toxicities often prevent delivery of optimal intensity and/or duration of standard frontline chemotherapy. Brentuximab vedotin (BV) and nivolumab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3e76d5b47e81fb0f1f244bc7e84accf2
https://doi.org/10.1182/blood-2019-124866
https://doi.org/10.1182/blood-2019-124866
Publikováno v:
Retinal casesbrief reports. 11(2)
Purpose To describe Waldenstrom's macroglobulinemia (WM) as a masquerade syndrome. Methods Case report. Results A 59-year-old human leukocyte antigen (HLA)-A29-negative white male presented with a 7-year history of floaters, progressive vision loss,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26c41ac6d24b9971a053238fd4263832
https://pubmed.ncbi.nlm.nih.gov/29621043
https://pubmed.ncbi.nlm.nih.gov/29621043